PressJuly 28, 2025 atai shares fall as partner Recognify's schizophrenia cognition trial misses primary endpoint
PressJuly 23, 2025 GH Research details global pivotal program for GH001 and full Phase 2b TRD dataset
PressJuly 22, 2025 Reunion publishes RE104 Phase 1 data in the Journal of Clinical Psychopharmacology
PressJuly 17, 2025 Cybin wins UK MHRA approval to begin EMBRACE, its second pivotal CYB003 depression study
PressJuly 15, 2025 Clearmind adds Johns Hopkins site to Phase I/IIa alcohol-use-disorder trial of CMND-100
PressJuly 15, 2025 Enveric's lead candidate EB-003 shows positive preclinical signal in a PTSD fear model
PressJuly 14, 2025 National coverage spotlights Texas's $50M state investment in FDA-supervised ibogaine research
PressJuly 11, 2025 Germany launches EU's first psilocybin compassionate-use program using Filament Health's PEX010
PressJuly 7, 2025 Algernon to Acquire NoBrainer Imaging Centers, Inc. – Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
PressJuly 7, 2025 Atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
PressJuly 7, 2025 Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
PressJuly 7, 2025 SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
PressJuly 7, 2025 Neural Therapeutics Announces SERFOR Permit Renewal Submission and Extension of LOI with HANF.COM
PressJuly 7, 2025 Filament Health Announces First Quarter 2025 Financial Results and Operational Highlights
PressJuly 7, 2025 Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
PressJune 5, 2025 Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
